{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:23:52Z","timestamp":1791829432650,"version":"4.3.4"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T00:00:00Z","timestamp":1738195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Adrenal tumors (ATs) encompass a wide differential diagnosis, necessitating a multi-step process for accurate identification. Liquid biopsy emerges as a promising non-invasive technique for distinguishing between malignant and benign, as well as hyperfunctioning and non-functioning cases. Recent studies have highlighted the potential of microRNAs as circulating biomarkers; however, their clinical utility remains underexplored. This study aims to validate the diagnostic performance of selected circulating microRNAs, (miR-483-5p, miR-210, miR-335 and miR-22-3p), identified through microRNA profiling studies, as markers of malignancy or cortisol hypersecretion in a cohort of patients with ATs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We collected serum samples from 75 patients with ATs, including 50 cases of adrenocortical adenomas (ACA) and 25 cases of adrenocortical carcinomas (ACC), along with 15 controls. In the ACC subgroup, 16 samples were obtained preoperatively or upon detection of recurrence (active ACC group), while the remaining from disease-free patients with long-term follow-up. Among the 56 patients with ATs evaluated preoperatively (50 with ACAs and 6 with ACC), 26 had non-functioning tumors, 22 exhibited mild autonomous cortisol secretion, and 8 had Cushing syndrome. Quantitative real-time polymerase chain reaction was employed to analyze microRNA expression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Circulating levels of miR-483-5p and miR-210 were significantly elevated in patients with active ACC compared to both ACAs (p&amp;lt;0.001 and p=0.004, respectively) and controls (p=0.02 and p = 0.03, respectively). Notably, miR-483-5p serum levels were higher in patients with active ACC compared to disease-free ACC patients (p = 0.01). MiR-483-5p demonstrated the best diagnostic accuracy for distinguishing active ACC cases from ACAs, achieving a sensitivity of 81.3% and a specificity of 88%, and from disease-free ACC patients, reaching sensitivity of 81.3% and specificity of 89%. MiR-22-3p serum levels successfully differentiated patients with Cushing syndrome from those with non-functioning ATs (area under the curve=AUC=0.800, 95% CI: 0.653\u20130.953, p=0.01) and controls (AUC= 0.800, 95% CI: 0.610\u20130.990, p=0.02). Additionally, circulating miR-22-3p levels exhibited a significant correlation with traditional diagnostic tests for hypercortisolism.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study supports the potential of a liquid biopsy approach as an innovative method for diagnosing and monitoring patients with ATs, offering a complementary tool to existing diagnostic methods.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2025.1511520","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T05:10:19Z","timestamp":1738213819000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Evaluation of microRNAs as liquid biopsy markers in adrenocortical tumors"],"prefix":"10.3389","volume":"16","author":[{"given":"Chrysoula","family":"Mytareli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassiliki","family":"Kalotychou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandros","family":"Lafioniatis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Kaltsas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George N.","family":"Zografos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athina","family":"Markou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Labrini","family":"Papanastasiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Fountas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitra Argyro","family":"Vasilliadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evanthia","family":"Kassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Mantzourani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Angelousi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1093\/ejendo\/lvad066","article-title":"European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors","volume":"189","author":"Fassnacht","year":"2023","journal-title":"Eur J Endocrinol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-18-0608","article-title":"European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors","volume":"179","author":"Fassnacht","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-022-03066-z","article-title":"Liquid biopsy for the assessment of adrenal cancer heterogeneity: where do we stand","volume":"77","author":"Perge","year":"2022","journal-title":"Endocrine"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2014.5","article-title":"Clinical relevance of circulating cell-free microRNAs in cancer","volume":"11","author":"Schwarzenbach","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3389\/fendo.2015.00195","article-title":"microRNAs as potential biomarkers in adrenocortical cancer: progress and challenges","volume":"6","author":"Cherradi","year":"2015","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-13-0051","article-title":"Serum miR-483-5p and miR-195 are predictive of recurrence risk in adrenocortical cancer patients","volume":"20","author":"Chabre","year":"2013","journal-title":"Endocr Relat Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2013.06.022","article-title":"MiR-34a and miR-483-5p are candidate serum biomarkers for adrenocortical tumors","volume":"154","author":"Patel","year":"2013","journal-title":"Surgery"},{"key":"B8","doi-asserted-by":"publisher","first-page":"5474","DOI":"10.1038\/s41598-017-05777-0","article-title":"Evaluation and diagnostic potential of circulating extracellular vesicle-associated microRNAs in adrenocortical tumors","volume":"7","author":"Perge","year":"2017","journal-title":"Sci Rep"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-017-1506-z","article-title":"Analysis of circulating extracellular vesicle-associated microRNAs in cortisol-producing adrenocortical tumors","volume":"59","author":"Perge","year":"2018","journal-title":"Endocrine"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.2013.148","article-title":"Analysis of circulating microRNAs in adrenocortical tumors","volume":"94","author":"Szab\u00f3","year":"2014","journal-title":"Lab Invest"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.19118","article-title":"New insights in the clinical and translational relevance of miR483-5p in adrenocortical cancer","volume":"8","author":"Salvianti","year":"2017","journal-title":"Oncotarget"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-00817","article-title":"MicroRNA expression profiling in adrenal myelolipoma","volume":"103","author":"Decmann","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B13","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jbiotec.2019.03.017","article-title":"Comparison of plasma and urinary microRNA-483-5p for the diagnosis of adrenocortical Malignancy","volume":"297","author":"Decmann","year":"2019","journal-title":"J Biotechnol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-0125","article-title":"The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline","volume":"93","author":"Nieman","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12030724","article-title":"Early postoperative circulating miR-483-5p is a prognosis marker for adrenocortical cancer","volume":"12","author":"Oreglia","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B17","article-title":"Evaluation of 9-cis retinoic acid and mitotane as antitumoral agents in an adrenocortical xenograft model","volume":"5","author":"Nagy","year":"2015","journal-title":"Am J Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-16-0249","article-title":"Preclinical progress and first translational steps for a liposomal chemotherapy protocol against adrenocortical carcinoma","volume":"23","author":"Jung","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/ejendo\/lvae022","article-title":"Circulating cell-free DNA-based biomarkers for prognostication and disease monitoring in adrenocortical carcinoma","volume":"190","author":"Lippert","year":"2024","journal-title":"Eur J Endocrinol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-13-0817","article-title":"MicroRNA expression patterns associated with hyperfunctioning and non-hyperfunctioning phenotypes in adrenocortical adenomas","volume":"170","author":"Vel\u00e1zquez-Fern\u00e1ndez","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-4456","article-title":"Oncogenic role of miR-483-3p at the IGF2\/483 locus","volume":"70","author":"Veronese","year":"2010","journal-title":"Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-11-0082","article-title":"The role of microRNA deregulation in the pathogenesis of adrenocortical carcinoma","volume":"18","author":"\u00d6zata","year":"2011","journal-title":"Endocr Relat Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.v143.4","article-title":"MiR-483-5p and miR-139-5p promote aggressiveness by targeting N-myc downstream-regulated gene family members in adrenocortical cancer","volume":"143","author":"Agosta","year":"2018","journal-title":"Int J Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2014.04.005","article-title":"MicroRNA expression patterns in adrenocortical carcinoma variants and clinical pathologic correlations","volume":"45","author":"Duregon","year":"2014","journal-title":"Hum Pathol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2010.085621","article-title":"Differential expression of microRNA-675, microRNA-139-3p and microRNA-335 in benign and Malignant adrenocortical tumors","volume":"64","author":"Schmitz","year":"2011","journal-title":"J Clin Pathol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-024-01005-8","article-title":"Circulating non-coding RNA biomarkers of endocrine tumors","volume":"20","author":"Butz","year":"2024","journal-title":"Nat Rev Endocrinol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1511520\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T05:10:21Z","timestamp":1738213821000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1511520\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,30]]},"references-count":26,"alternative-id":["10.3389\/fendo.2025.1511520"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1511520","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,30]]},"article-number":"1511520"}}